New York Genome Center

05/05/2025

In The State of CRISPR and Genome Editing virtual summit, GEN brings together an outstanding line-up of pioneers and practitioners in genome editing to provide a compelling and candid overview of the field.

04/24/2025

The research partially received support from the National Cancer Institute.

04/22/2025

Plus, the 1803 Fund pledged $75 million to Oregon groups that serve Black youths, and the Bezos Earth Fund and the Global Methane Hub will give $27.4 million to lower methane emissions through livestock breeding programs.

03/27/2025

Researchers have developed Paired-Damage-seq, a method combining single-cell RNA sequencing with DNA damage analysis to reveal genome vulnerabilities linked to disease risk...

03/17/2025

For decades, government funding “has positioned the United States as a global leader” in science, says scientist Tom Maniatis of Columbia’s Zuckerman Institute and the New York Genome Center. He highlights how a new National Institutes of Health policy cutting money for research “jeopardizes” this, in Cell: https://tinyurl.com/ubw6uphe

See our related animation on these NIH funds: https://youtu.be/DawuYYRSAgE?si=t53swV7GovsCl-px

02/11/2025

NIH's new policy (NOT-OD-25-068) capping indirect cost reimbursement at 15% threatens the future of research, training, and scientific infrastructure at research institutions nationwide. In response, the NYGC has drafted a petition urging its reversal.

Please join us by signing and circulating this petition within your networks.

Petition to Reverse the NIH Indirect Cost Cap (NOT-OD-25-068)

01/23/2025

Genes are mapping the way to cancer cures.

12/02/2024

Methods for exploring the geography of molecular-scale processes within tissue samples are transforming cancer research, but the toolbox can be daunting.

11/08/2024

A new type of CRISPR gene-editing technology has revealed the crucial cellular functions of noncoding RNAs, once considered genetic junk, and suggests they could be useful targets for personalized cancer treatments.

10/18/2024

Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal circular DNA in tumor cells drives resistance to therapy. These discoveries open new therapeutic avenues. A groundbreaking study led by researchers at Weill Cornell Medicine and

10/04/2024

Privacy concerns in RNA sequencing - new method quantifies single-cell data’s risk of private information leakage